Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Thursday that it has introduced Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan.

This product launch is a result of Upsher-Smith's strategic partnership with RAFARM UK that includes the development and distribution of six ophthalmic and otic ANDA products.

According to IQVIA, the brimonidine tartrate and timolol maleate ophthalmic solution market had United States sales of around USD392m for the 12 months ending February 2023.